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thlete Screening
or Occult Cardiac Disease
o Risk, No Fun?*
othar Faber, MD, FESC, FACC,
rank van Buuren, MD
ad Oeynhausen, Germany
egular physical exercise promotes health and longevity.
oung, well-conditioned competing athletes are believed to
e one of the healthiest segments of society and a brilliant
xample of the beneficial effects of sport. Therefore, sudden
ardiac death (SCD) in such persons is not only devastating
o all directly involved—the athlete him- or herself who is
nexpectedly converted into a victim, as well as his or her
amily, team, and caregivers—such a death is also disturbing
o the public and regularly draws a great deal of media
ttention.
See page 1033
The current hypothesis for nontraumatic SCD in young
thletes is that a fatal arrhythmia may be triggered by
igorous exercise in those who have certain occult cardiac
isorders that do not necessarily interfere with exercise
olerance. Hypertrophic cardiomyopathy (HCM) has been
escribed as the leading abnormality predisposing to SCD
n young athletes in the U.S. (1). Dilated forms of cardio-
yopathy are more frequent in other countries (1–3).
Sudden cardiac death is believed to be uncommon, with
stimates of approximately 0.5 to 2.0 per 100,000 person-
ears. The true incidence, however, is unknown and may be
igher for several reasons. Pathologists carrying out post-
ortem examinations may be inexperienced with all the
ardiac conditions potentially responsible; some conditions
ay thus remain undiagnosed. Retrospective data from
eferral centers regarding the cause of SCD in athletes may
e subject to bias depending on the centers’ particular
xpertise; comprehensive prospective data are scarce. Fi-
ally, conditions such as cardiac ion channel diseases may
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.L
From the Department of Cardiology, Heart and Diabetes Center North-Rhine
estphalia, Ruhr-University Bochum, Bad Oeynhausen, Germany.redispose to fatal arrhythmias but do not present as
tructural abnormalities.
Although a consensus has been achieved that athletes with
nown and significant cardiovascular abnormalities should be
isqualified from competition (4–6), there is controversy over
hether to actively screen for these abnormalities. Attitudes
ary considerably, from no screening at all to obligatory nation-
ide pre-participation screening, and include both nonprofit
nd for-profit initiatives. Some apparently robust data concern-
ng the problem of preventing SCD in young athletes derive
rom the Italian approach (2,3). This strategy consists of
bligatory pre-participation screening including history, phys-
cal examination, and electrocardiogram (ECG) and proceeds
o cardiac imaging in the case of abnormalities (reported in
oughly 10% of participants). One of the major publications on
his approach (2) reported 22 cases diagnosed with HCM in
4,000 probands screened (0.07%). Sudden cardiac death from
CM has been described as virtually absent in Italian sports
enues, whereas SCD from cardiac diseases less obvious on
CG and echocardiography continued to occur, but at a
ignificantly reduced rate. An overall disqualification rate of 2%
as been reported (2,3).
The authors of the present study in this issue of the
ournal (7) performed 12-channel ECG and echocardiog-
aphy in 3,500 British athletes, mainly Caucasian, compet-
ng in endurance disciplines on a national level. A total of 53
robands exhibited a left ventricular wall thickness 12 mm,
0 of whom also manifested cavity dilatation and a normal
ransmitral flow pattern (8) suggestive of adaptive left
entricular hypertrophy (LVH). The remaining 3 probands,
ll of whom were also suspected of having adaptive LVH,
ere intensively studied (cardiac magnetic resonance imag-
ng and genotyping) or detrained. Interestingly, 2 of these 3
robands were of African descent. No definitive diagnosis of
CM could be made. The overall yield of screening was an
electrical” diagnosis (Wolff-Parkinson-White syndrome or
ong-QT syndrome) in 15 participants (0.4%) and a “struc-
ural” cardiac abnormality (valvular or congenital heart
isease or LVH) in 64 participants (1.8%). The authors
oncluded that routine echo screening of high-level athletes
or the presence of HCM is not cost-effective and that
ntensive sporting activity naturally selects out HCM.
Overall, the data presented are welcome because they
roaden the global experience on athlete screening for occult
ardiac abnormalities, which were found in about 2% of
ubjects. On the other hand, the 0 incidence of HCM in
his cohort does not really come as a surprise when com-
ared with the Italian database, which was 10 times larger.
urthermore, all 3 cases initially suggestive of HCM would
ave undergone imaging anyway if examined within the
talian program because of their abnormal ECG tracings.
he conclusion that echocardiographic screening is not
ecessary if only HCM is targeted, and that the ECG is
eliable enough to pick up cases suggestive of pathological
VH, thus appears to be justified and is consistent with the
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March 11, 2008:1040–1 Editorial Commenttalian data. The other conclusion, that HCM is extremely
ncommon in elite athletes, should be taken with caution. As
he authors state in their limitations section, results may be
ifferent for non-Caucasians and for those whose sport disci-
lines are less dependent on cardiorespiratory endurance.
In addition, when judging the overall value of echocar-
iographic screening in young athletes, structural abnormal-
ties other than HCM should also be considered. In the
resent study, 11 cases (0.3%) of unsuspected congenital or
alvular heart disease were found, although of a mild degree
nd obviously not interfering with exercise tolerance. Such a
nding is good to know, especially for an elite athlete.
urthermore, a negative pre-participation echo at entry,
specially when archived with current digital technology,
ay be extremely helpful if symptoms or other health
roblems come up later. This indeed happens, as demon-
trated by the authors of the present study, who described an
xperienced marathon runner who dropped dead and was
ound to have myocardial fibrosis on autopsy (9) or by those
rofessional cyclists who apparently suffered cardiac damage
uring their careers (10).
There are some other specific aspects that deserve to be
ept in mind. First, a multitude of interests and aspects may
nterfere with the proband/patient-physician relationship,
ometimes putting into question the reliability of history
ata as provided by the probands. Doping affairs occur
lmost every other week, obviously involving some physi-
ians and biomedical scientists. These affairs indicate that an
nknown percentage of athletes and their caregivers are
illing to run the risk of health damage, including prema-
ure death, in return for success, fame, and money. In
ddition, in contrast to the field of “normal” medicine with
ts increasingly restrained resources and cost-effectiveness
alculations, professional sport is a growing multibillion-
ollar business; screening costs appear to be absolutely
egligible in this context. Even the amateur marathon
unner can be reassured that the price of a screening
chocardiogram is probably less than that of the latest
unning shoes. Societies with a public health care system
ight also take into account that the yearly costs of care for
n occasional persistent vegetative state after a “successful”
esuscitation in a victim of SCD may easily surpass thou-
ands of screening echocardiograms. Finally, in this
sually easy-to-scan population, a structured echo exam-
nation may be less time-consuming than a careful
hysical examination; modern echocardiography, includ-
ng remote expert reading and parametric imaging, may
rovide objective and quantitative information on global
nd regional myocardial function beyond diameters and
jection fraction (11).
Our personal and institutional bias, therefore, is tooutinely screen professional athletes, including performingchocardiography, in close cooperation with their teams and
ational sports organizations and to follow up these athletes
uring their careers. For nonprofessionals and nonelite
thletes, we recommend, as a minimum, clinical and ECG
creening as proposed in the European consensus reports
5,6). We strongly believe that the heart and circulatory
ystem of the competing athlete deserve the same level of
wareness and attention that has been directed toward the
usculoskeletal system for decades. On the other hand, as
emonstrated by the first marathon runner, Pheidippides, as
arly as 490 BC, it has to be recognized that complete risk
limination is not possible.
eprint requests and correspondence: Dr. Lothar Faber, Depart-
ent of Cardiology, Heart and Diabetes Center NRW, Ruhr-
niversity Bochum, Georgstr. 11, D-32545 Bad Oeynhausen,
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